Engflag

Vomitil

Quick links to important sections

Vomitil

Vomitil_DE

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vomitil

Quick Facts

Property Description
Active Ingredient Prochlorperazine Maleate
Forms Tablet, Suppository, Injectable Solution, Buccal Tablet
Pharmacological Class Phenothiazine Antiemetic / First-Generation Antipsychotic
General Purpose Control of severe nausea and vomiting
Origin Synthetic, Phenothiazine derivative

Vomitil: A Foundational Phenothiazine Antiemetic

Vomitil is a specialized, prescription-only medication whose active ingredient is Prochlorperazine Maleate, a potent agent used to manage conditions involving severe nausea and psychotic symptoms. It is classified as both an antiemetic and an antipsychotic agent, and the drug belongs to the high-level chemical category of phenothiazine derivatives. Prochlorperazine Maleate is clinically recognized for its reliable action in the central nervous system and its efficacy in blocking the emetic response.

This drug entity is a single-component product originating as a synthetic compound within the piperazine subgroup of phenothiazines. Its primary action is that of a dopamine antagonist. Its key mechanism involves blocking dopamine receptors, working by directly influencing key chemical signaling in the brain. This chemical foundation gives Prochlorperazine Maleate its therapeutic duality, reflecting its status as a first-generation antipsychotic.

General Purpose and Mechanism Summary

The medicine's general purpose is to provide powerful control over acute and severe nausea and uncontrolled vomiting that may be resistant to less potent treatments. It achieves this primarily through a depressant action on the brain's chemoreceptor trigger zone (CTZ). Beyond its antiemetic capability, Vomitil serves the secondary purpose of managing agitated symptoms associated with specific psychotic disorders and providing short-term relief for severe, unmanageable non-psychotic anxiety.

Available Forms and Variations

Prochlorperazine Maleate is manufactured in various dosage form(s) to ensure effective administration regardless of the patient's condition. These forms include the standard oral tablet, the rectal suppository, the injectable solution for parenteral (intramuscular or intravenous) administration, and the buccal tablet.

This form-based versatility is a critical attribute, as it allows the drug to be administered via different routes of administration, such as the rectal or parenteral route, which bypass the need for oral swallowing. This capability ensures that the antiemetic can be delivered rapidly and retained in the system even when the patient is suffering from continuous, debilitating vomiting.

Regulatory References

  1. rectal suppository

What side effects are possible with Vomitil?

The safety profile of Prochlorperazine Maleate is documented by official regulatory sources and reflects its classification as a phenothiazine agent, primarily affecting the central nervous system and cardiovascular system. The official list of possible adverse effects is categorized by frequency and the physiological system affected.

Adverse reactions that are frequently observed, or Common, typically involve the Nervous System, including drowsiness (somnolence) and dizziness. Uncommon effects include anticholinergic manifestations such as dry mouth and constipation.

Serious Adverse Reactions

Regulatory documents highlight several serious adverse reactions. The most clinically significant are the Extrapyramidal Symptoms (EPS), which can manifest as movement disorders. Acute Dystonic Reactions are often more likely at the start of treatment or during dose increases. A potentially irreversible condition, Tardive Dyskinesia (TD), is associated with long-term exposure to phenothiazine antipsychotics.

A rare, life-threatening neurological condition, Neuroleptic Malignant Syndrome (NMS), is explicitly recognized as a risk. Rare effects on the blood system, such as agranulocytosis, and cardiovascular effects like QT prolongation and serious arrhythmias, are also documented.

Population-Specific Safety

Specific safety considerations are mandated for certain groups. A Boxed Warning is in place regarding the increased risk of death when treating older adults with dementia-related psychosis with antipsychotic drugs, a risk that extends to Prochlorperazine. Use is generally restricted in children under 2 years of age or under 9 kg (20 lbs). The drug is also contraindicated in conditions such as circulatory collapse and blood dyscrasias, and should be used with caution in patients with severe hepatic impairment.

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information for Vomitil

This section outlines the officially documented manifestations of Prochlorperazine Maleate (Vomitil) overdose and the regulatory requirements for seeking emergency medical attention, as stated in authoritative government labeling.

Overdose Scope

Feature Official Regulatory Statements
Documented overdose presentations Overdose may present with CNS depression, ranging from deep sedation to coma. Other neurological signs include extrapyramidal symptoms (EPS), tremor, convulsions, and generalized hypotension.
Physiological systems affected The primary systems documented to be affected are the Central Nervous System, Cardiovascular System, and Respiratory System.
Population-specific overdose notes Elderly patients are noted in labeling to be more susceptible to the severe effects and toxicity of phenothiazines.
Emergency-response statements Immediate medical attention must be sought for any known or suspected overdose. Urgent help is required upon manifestation of profound hypotension, respiratory depression, coma, or cardiac arrhythmias.

Overdose Classifications (High-level)

Classification Official Regulatory Statements
Severity classification The scenario is classified as a severe and potentially life-threatening emergency.
Overdose-context constraints No specific antidote is known. Management must be strictly symptomatic and supportive, and epinephrine is expressly contraindicated for treating overdose-induced hypotension.

Official Overdose Statements

  • Overdose may lead to profound hypotension, cardiac arrhythmias (such as ventricular fibrillation), and respiratory depression.
  • No specific antidote is known; treatment relies on supportive measures and procedures like early gastric lavage or use of activated charcoal.
  • Management involves intensive observation and monitoring, including continuous ECG monitoring, and maintaining an adequate airway.

Connection to the overall overdose profile

The regulatory documents define the overdose profile by listing severe central nervous system and cardiovascular manifestations that necessitate immediate contact with emergency services. This information clarifies that intervention must be entirely symptomatic and supportive, as the labels state that no specific antidote is available and certain treatments are contraindicated.

Therapeutic Uses of Vomitil

What Vomitil Treats: Main Uses and Benefits

Vomitil is commonly used to help with a range of conditions, offering supportive relief across several distinct therapeutic domains. The medication is relevant for easing acute and severe emetic symptoms and the management of specific neuropsychiatric manifestations. Its clinical applications include severe nausea and vomiting, certain psychotic disorders, and severe, unmanageable non-psychotic anxiety.

Quick Fact: Relief for Acute Symptomatic Distress

The medication is commonly used to help with symptoms related to systemic imbalance that lead to episodes of acute and severe emetic symptoms. This use is often applied in scenarios where additional symptomatic support is needed, such as in postoperative care or during treatments that cause intense nausea. This assists with maintaining functional stability and supports the patient's ability to retain necessary fluids and oral medications. For its neuropsychiatric application, Vomitil may offer support that helps ease the overall symptom burden during symptomatic phases.

Regulatory References

  1. NIH StatPearls Overview on Prochlorperazine

Eligibility and Restrictions for Use

Official Population Eligibility Rules

The eligibility for Vomitil (Prochlorperazine Maleate) is defined by strict regulatory criteria, specifying absolute exclusions and populations requiring conditional use.

Contraindicated Populations Absolute Non-Eligibility
Age/Weight Children under 2 years of age or under 20 lbs (9.1 kg).
Physiological State Patients in a comatose state or with severe CNS depression.
Comorbidities Known hypersensitivity to phenothiazines, bone marrow depression, or blood dyscrasias.
Specific Risk Older adults with dementia-related psychosis (due to increased mortality risk).

Age-Related and Conditional Use

Use is not recommended for non-psychotic indications in children aged 2 to 12 years unless the benefit outweighs the potential risk. Use in pregnant patients is generally not recommended and is contraindicated during the third trimester due to risks to the newborn. The drug requires caution in patients with impaired liver function, cardiovascular disorders, glaucoma, or a history of seizures.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Prochlorperazine Maleate is primarily defined by documented pharmacodynamic and pharmacokinetic mechanisms consistent with official regulatory labeling.

Formal Interaction Restrictions

Co-administration is formally contraindicated with certain drugs known to prolong the QTc interval, such as specific antiarrhythmics and antipsychotics, due to the increased risk of severe cardiac arrhythmias. The use of large amounts of alcohol or other Central Nervous System (CNS) Depressants (e.g., narcotics, barbiturates) is also prohibited due to documented additive CNS depressant effects.

Exposure and Pharmacodynamic Effects

Official regulatory information notes that Prochlorperazine is a substrate for metabolism by multiple hepatic enzymes, including CYP2D6, indicating a mechanism for exposure alteration with co-administered enzyme modulators. Cautionary statements are documented for concurrent use with Lithium and Propranolol, which may result in altered plasma concentrations of both medications. Furthermore, additive pharmacodynamic effects require consideration when combining with anticholinergic agents (risk of severe autonomic effects) and antihypertensives (risk of exaggerated hypotension).

Timing and Population Cautions

One specific timing restriction is documented: Prochlorperazine must be discontinued 24 hours prior to the administration of the radiological contrast medium Metrizamide. Official notes also indicate that interaction risks, such as postural hypotension and anticholinergic effects, may be more pronounced in elderly patients.

Mechanism of Action

Blocking Signals in the Chemoreceptor Trigger Zone (CTZ)

Vomitil primarily acts as an antagonist at Dopamine D2 receptors ( D2 R) within the Chemoreceptor Trigger Zone (CTZ) of the brain. By occupying these receptors, the compound increases the neural excitability threshold required for the CTZ to transmit signals to the expulsion center. This interruption of the signaling cascade results in the suppression of the involuntary protective expulsion reflex.

Modulating Balance and Autonomic Tone

The compound additionally engages Histamine H1 and Acetylcholine Muscarinic receptors ( mAChR) in central nervous system regions associated with equilibrium. This multi-target mechanism reduces nerve impulse transmission originating from the vestibular system, leading to the modulation of the body's response to motion signals. The resulting combined action produces a state of diminished responsiveness across the targeted pathways and influences general autonomic tone.

Dosage and Administration Information

How Vomitil (Prochlorperazine Maleate) is Used

Vomitil is administered through multiple routes, and its dosage and frequency are dependent on the condition being managed.

Official Routes and Administration Principles

The medication is available for oral ingestion (tablets), rectal insertion (suppositories), and parenteral delivery via intramuscular (IM) or intravenous (IV) injection. A buccal tablet form is also available, designed to be placed high under the upper lip where it dissolves; this form must not be swallowed whole or chewed.

For acute, severe nausea and vomiting, the parenteral route is used. IV administration requires a controlled infusion rate that must not exceed 5 mg per minute. The injectable solution must be visually inspected and discarded if discoloration is observed prior to use.

Dosing and Frequency Patterns

Indication Adult Dose/Frequency Pattern (General)
Severe Nausea/Vomiting Oral 5–10 mg, 3 to 4 times daily (Max 40 mg/day). IM/IV 5–10 mg, repeated every 3–4 hours.
Psychotic Disorders Initial oral 10 mg 3 to 4 times daily; titrated up to maintenance of 50–150 mg daily in divided doses.
Non-Psychotic Anxiety Oral 5 mg, 3 to 4 times daily (Max 20 mg/day).

Use of Vomitil for non-psychotic anxiety is designated as short-term, typically not exceeding 12 weeks. Maintenance dosing for psychotic disorders requires periodic re-evaluation, and the dose should be gradually reduced once symptom control is established. A lower initial dose is generally advised for older adults, and the drug is not recommended for children under 2 years of age or under 20 pounds.

Recent Clinical Evidence

Research evidence / Overview of studies for Vomitil

Evidence for Controlling Severe Nausea and Vomiting

Research related to Vomitil (Prochlorperazine Maleate) in the context of acute sickness was studied for outcomes related to emesis. The evidence base consists primarily of Randomized Controlled Trials (RCTs) and Systematic Reviews where the drug was evaluated in specific scenarios, such as post-operative care and acute vomiting in emergency settings. These studies focused on outcomes describing episodic or acute changes, such as the time interval until symptom measurement and whether additional antiemetic medication was needed. Research has involved adults in acute care and pediatric patients older than two years of age.

Studies and reviews describe patterns observed in the studies, focusing on the time to symptom measurement for outcomes related to physical discomfort. Findings contribute to the body of evidence. Observed outcomes were primarily short-term and focused on the immediate period following administration.

However, the evidence is primarily derived from studies conducted during periods of increased symptom activity and focuses on short-term symptom measurement. Comparative evidence is lacking against all newer classes of antiemetic drugs. Furthermore, there is limited information for long-term outcomes or sustained symptom measurement beyond the initial acute episode. The results apply only to the populations studied and do not provide extensive insight into complex, chronic nausea patterns.

Evidence for Managing Symptoms of Psychotic Disorders

Vomitil also was evaluated in clinical trials as a first-generation agent for conditions involving periods of heightened symptoms related to certain psychotic disorders. Research examined its use in acute episodes and for the management of chronic conditions. These trials studies monitored changes in standardized functional scales that measure the intensity of symptoms like agitation, hallucinations, and delusions.

Studies report how symptoms evolved in observed populations, noting patterns related to positive symptoms. Research was associated with changes measured during the study period, which contributes to the understanding of symptom patterns in these specific contexts.

Evidence for Short-Term Treatment of Severe Anxiety

The research for this medication in the context of severe, non-psychotic anxiety is structured around short-term, controlled clinical studies that studies explored outcomes related to systemic or functional imbalance. The research data describe patterns related to symptomatic changes that was observed in some studies over short periods, primarily in the initial weeks of use. A significant limitation is that the research only supports its use for a short, defined period. Follow-up durations were limited, and long-term evidence is limited beyond a period of up to 12 weeks.

Evidence in Specific Patient Populations

The research has included pediatric patients older than two years of age for both its antiemetic and psychiatric applications. However, regulatory bodies have highlighted that use in older adults with dementia-related psychosis was associated with significant risks in studies, and its use in this population is a key area of regulatory concern. For other specific groups, such as patients with significant organ impairment or certain comorbidity-defined groups, data for certain groups remain insufficient. The results apply only to the populations studied.

Research Gaps and Areas of Uncertainty

One key gap is the comparative evidence, as there are limited head-to-head studies against many modern alternative antiemetic and antipsychotic drugs. The evidence quality may vary across studies, with some sample sizes being modest or the findings being heterogeneous. Furthermore, the research is ongoing in certain areas outside of the currently established indications, meaning the data are still emerging for these scenarios. The evidence highlights what is known — and what is still uncertain.

Key Studies & References

  1. Prochlorperazine: Drug Information (NIH MedlinePlus)
  2. NICE Guideline: Psychosis and schizophrenia in adults: prevention and management (Guideline context for FGA use)

Frequently Asked Questions (FAQ)

Common questions about Vomitil (FAQ)

Q: How long does it take for Vomitil to start working and when should I feel better?

Amoxicillin begins to act against bacteria shortly after the first dose is taken. Clinical experience suggests that symptom improvement may begin within 2 to 3 days of starting treatment. While you may start feeling better quickly, it is generally recommended to complete the full prescribed course to help ensure the infection is fully resolved and minimize the risk of bacterial resistance. If there is no sign of improvement, or if symptoms worsen, contact your healthcare provider for further guidance.

Q: Can I stop taking Vomitil if my symptoms go away?

Official product information stresses the importance of taking the medication exactly as prescribed by your healthcare provider. Discontinuing treatment early may increase the risk of antibiotic resistance and the return of the infection. Even if symptoms have cleared, the full prescribed course is necessary to eradicate all the target bacteria. Any change to the treatment plan should only be made after consulting with a healthcare professional.

Q: What is the best way to take Vomitil, with food or on an empty stomach?

Amoxicillin can be taken with or without food. Taking it with a meal may help reduce potential stomach upset in some people. It is generally advised to take the dose with a glass of water.

How should Vomitil be stored and disposed of?

Vomitil (Prochlorperazine Maleate) must be stored and disposed of according to strict requirements defined in official regulatory labeling.

Storage Requirement Official Condition
Temperature Store at Controlled Room Temperature, between 15 C and 30 C (59 F and 86 F). Do not freeze.
Protection Keep protected from light, excess heat, and moisture.
Container Dispense and store in a tight, light-resistant container with a child-resistant closure.
Safety Must be kept out of the reach of children. Do not use past the expiration date.

For disposal, unused or expired medication should be taken to a community drug take-back program. If a take-back option is unavailable, the tablets should be mixed with an unappealing substance, placed in a sealed bag or container, and discarded in the household trash. This product is not recommended for flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Vomitil found in:

A-Z Index: